Abstract:Background: In patients with schizophrenia, Diankuang Mengxing Decoction with antipsychotics is one of the treatments for it. However, little information is available regarding the difference between the therapeutic effect of Diankuang Mengxing Decoction with antipsychotics and other treatments. Systematic evaluation is conducted to assess the efficacy and safety of Diankuang Mengxing Decoction and other antipsychotics, which are used to treat schizophrenia. Methods: We performed a systematic review (PROSPERO ID: CRD42023414603). This entailed a computerized search of several research databases from their respective dates of establishment until April 11, 2023, which collected clinical randomized controlled trials of Diankuang Mengxing Decoction combined with antipsychotics. The databases that contributed to this study were PubMed, Web of Science, Embase, EBSCOhost, Cochrane, Scopus, and Google Scholar. Each publication was screened according to defined inclusion and exclusion criteria, and appropriate literature was extracted and evaluated for quality, for which meta-analysis was performed using RevMan 5.4. Results: A literature review of 456 publications resulted in the inclusion of 18 randomized controlled trials with data collected from a total of 1636 patients. Meta-analytical results showed combination with risperidone, olanzapine, chlorpromazine, clozapine, ziprasidone, or aripiprazole increased the overall effectiveness of Diankuang Mengxing Decoction when treating schizophrenia (P < . 00001), among whom olanzapine demonstrated the greatest enhancement (Z = 3.65, odds ratio = 4.26, 95% CI: 1.96-9.28, P = .0003). The 4-week/30-day treatment (P = .0003) and a dosage of 400 mL/d of Diankuang Mengxing Decoction (P = .0004) were more effective. Also, there were widespread reductions to the Positive And Negative Syndrome Scale (PANSS) total scores, PANSS-positive symptom scores, PANSS-negative symptom scores, general psychopathology scores (P < .05 for all), as well as the incidence of adverse effects (Z = 2.79, odds ratio = 0.34, 95% CI: 0.16-0.73, P = .005) in patients with schizophrenia. Conclusion: The combination of Diankuang Mengxing Decoction with different antipsychotics can improve the overall prognosis of patients with schizophrenia; Diankuang Mengxing Decoction combined olanzapine, a dosage of 400 mL/d and a duration of 4 weeks/30 days being the best in this regard, by alleviating the symptoms and diminishing the disorder's adverse effects. To build on this work, more large-sample, multi-center, and high-quality clinical studies in the future would help to further validate our findings.

Clinical study on Shuxuening combined with antipsychotics in treating chronic schizophreniacombined with antipsychotics in treating chronic schizophrenia

A double blinded multicenter clinical trial for evaluating the efficacy and safety of aripiprazole and risperidone in the treatment of schizophrenia

Protocol for a Pharmacogenomic Study on Individualised Antipsychotic Drug Treatment for Patients with Schizophrenia.

Effectiveness and safety of blonanserin for improving social and cognitive functions in patients with first-episode schizophrenia: a study protocol for a prospective, multicentre, single-arm clinical trial

The Efficacy and Safety of Sulforaphane As an Adjuvant in the Treatment of Bipolar Depressive Disorder

Improvement of Social Functioning in Patients with First-Episode Schizophrenia Using Blonanserin Treatment: a Prospective, Multi-Centre, Single-Arm Clinical Trial

Evaluation of the efficacy and safety of Suxiao Jiuxin Pill in the treatment of stable angina: A randomized, double-blind, placebo-controlled, multi-center clinical trial

Efficacy and safety of a Chinese medicine formula Diankuang Mengxing Decoction combined with antipsychotics in the treatment of schizophrenia: A meta-analysis of randomized controlled trials

Effect of Shen Xian Kang Decoction Combined Mycophenolate Mofetil in Patients with Proliferative Sclerosing IgA Nephropathy

Study on Clinical Efficacy of Guizhi-fuling Mixture Combined with Risperidone Tabiets in Treatment of Chronic Schizophrenia

Double-blind,double-dummy and randomized controlled study of aripiprazole in the treatment of acute schizophrenia

Clinical Study of Psychological Intervention Combined with Antipsychotics for Schizophrenia

Xin Su Ning—A Review of Basic and Clinical Pharmacology Integrated With Traditional Chinese Medicine Antiarrhythmic Theory

Investigation of the Cellular Pharmacological Mechanism and Clinical Evidence of the Multi-Herbal Antiarrhythmic Chinese Medicine Xin Su Ning

Efficacy and Safety of Shenqisuxin Granule for Non-ST-segment Elevation Acute Coronary Syndrome: Study Protocol for a Randomized, Double-Blinded, Placebo-Controlled Trial

Evaluation of clinical efficacy of Shuxuening injection combined with puerarin in the treatment of coronary heart disease with unstable angina pectoris

Sodium Nitroprusside Treatment for Psychotic Symptoms and Cognitive Deficits of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial

The Effectiveness And Safety Of Amisulpride In Chinese Patients With Schizophrenia: An 8-Week, Prospective, Open-Label, Multicenter, Single-Arm Study

Safety and Effectiveness of Blonanserin in Chinese Patients with Schizophrenia: an Interim Analysis of a 12-Week Open-Label Prospective Multi-Center Post-marketing Surveillance.

Efficacy and Safety of Suxiao Jiuxin Pills in the Treatment of Chronic Coronary Syndrome with Intolerance to Adverse Effects of Long-acting Nitrates: A Multicenter, Randomized, Double-blind, Placebo-controlled Study

Effect of Antipsychotic Medication Alone Vs Combined with Psychosocial Intervention on Outcomes of Early-Stage Schizophrenia: A Randomized, 1-Year Study.